2014
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Search citation statements
Paper Sections
Select...
553
174
154
19
Citation Types
42
665
6
31
Year Published
2013
2026
Publication Types
Select...
756
30
22
7
Relationship
37
778
Authors
Journals
Cited by 805 publications
(744 citation statements)
References 18 publications
42
665
6
31
“…In this study, 1 case of nonserious intraocular inflammatory response was reported. This incidence of 0.03% is consistent with previous reports of IVT-AFL treatment 7 , 13 , 15 , 16 , 24 , 25 . Increased IOP after intravitreal anti-VEGF injection is a potential effect 26 .…”
Section: Discussionsupporting
confidence: 92%
“…In this study, 1 case of nonserious intraocular inflammatory response was reported. This incidence of 0.03% is consistent with previous reports of IVT-AFL treatment 7 , 13 , 15 , 16 , 24 , 25 . Increased IOP after intravitreal anti-VEGF injection is a potential effect 26 .…”
Section: Discussionsupporting
confidence: 92%
“…Increased IOP after intravitreal anti-VEGF injection is a potential effect 26 . The incidence of OH and increased IOP in this cohort was 0.52% (Table 3 ) and is comparable to that reported previously 7 . Also, increased IOP was more likely develop during IVT-AFL treatment in eyes with comorbidities or medical history of glaucoma or OH 27 .…”
Section: Discussionsupporting
confidence: 91%
“…These are lower percentages than seen in the View study (Schmidt‐Erfurth et al. ), where around 90% were stable after 2 years; however, the definition of maintaining VA was <15 letters loss, whereas it was defined as <5 letters loss in our study. Thus, even in the group that start with poor baseline VA, and where outcome VA is expected to be low, treatment is still worthwhile because they often gain many letters and stabilize at a higher level than before.…”
Section: Discussioncontrasting
confidence: 92%
“…Central retinal thickness (CRT) evaluation was not corrected for OCT device type in the MATE‐EX study. Nevertheless, our data were in line with the VIEW, ALTAIR, ARIES, HAWK and HARRIER studies (Dugel et al, 2021; Mitchell et al, 2021; Ohji et al, 2020; Schmidt‐Erfurth et al, 2014), and other real‐world data (Eleftheriadou et al, 2018; Gayadine‐Harricham et al, 2020), showing that initial reductions in CRT occur following anti‐VEGF treatment and are sustained out to Months 24, 36 and 48. This supports the sustained effectiveness of a TEF posology.…”
Section: Discussionsupporting
confidence: 91%
